• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

西妥昔单抗联合安罗替尼治疗阴茎癌复发的病例报告

Case report of penile cancer recurrence treated with cetuximab combined with anlotinib.

作者信息

Dai Shuang, Liu Yan-Yang, Liu Tao, Zhang Yu, Luo De-Yun

机构信息

Lung Cancer Center Department of Medical Oncology West China Hospital Sichuan University Chengdu China.

Department of Oncology The First Affiliated Hospital of Chengdu Medical College Chengdu Medical College Chengdu China.

出版信息

Clin Case Rep. 2022 Feb 15;10(2):e05443. doi: 10.1002/ccr3.5443. eCollection 2022 Feb.

DOI:10.1002/ccr3.5443
PMID:35223013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8847399/
Abstract

Penile squamous cell carcinoma with pelvic lymph node metastases/recurrence has a poor prognosis. We reported a case with recurrent pSCC was administered cetuximab and anlotinib after failure of first-line treatment and achieved an effective response. Cetuximab combined with anlotinib may be a new choice for relapsed pSCC.

摘要

伴有盆腔淋巴结转移/复发的阴茎鳞状细胞癌预后较差。我们报告了1例复发性阴茎鳞状细胞癌患者，在一线治疗失败后接受了西妥昔单抗和安罗替尼治疗，并取得了有效反应。西妥昔单抗联合安罗替尼可能是复发性阴茎鳞状细胞癌的一种新选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6eaf/8847399/573165e1376f/CCR3-10-e05443-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6eaf/8847399/675d23cbfb87/CCR3-10-e05443-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6eaf/8847399/fcdc479e2307/CCR3-10-e05443-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6eaf/8847399/573165e1376f/CCR3-10-e05443-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6eaf/8847399/675d23cbfb87/CCR3-10-e05443-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6eaf/8847399/fcdc479e2307/CCR3-10-e05443-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6eaf/8847399/573165e1376f/CCR3-10-e05443-g002.jpg

相似文献

1
Case report of penile cancer recurrence treated with cetuximab combined with anlotinib.西妥昔单抗联合安罗替尼治疗阴茎癌复发的病例报告
Clin Case Rep. 2022 Feb 15;10(2):e05443. doi: 10.1002/ccr3.5443. eCollection 2022 Feb.
2
Multimodal Treatment Combining Salvage Surgery-Assisted Chemotherapy and Checkpoints Blockade Immunotherapy Achieves Complete Remission on a Recurrent Penile Cancer Patient: A Case Report.挽救性手术辅助化疗与检查点阻断免疫疗法相结合的多模式治疗使一名复发性阴茎癌患者实现完全缓解：病例报告
Onco Targets Ther. 2021 Sep 22;14:4891-4896. doi: 10.2147/OTT.S319932. eCollection 2021.
3
Case report of penile squamous cell carcinoma continuous treatment with BRCA2 mutation.阴茎鳞状细胞癌伴 BRCA2 突变的连续治疗病例报告。
World J Surg Oncol. 2024 Feb 9;22(1):50. doi: 10.1186/s12957-024-03305-9.
4
Immune landscape and immunotherapy for penile cancer.阴茎癌的免疫景观与免疫疗法。
Front Immunol. 2022 Nov 29;13:1055235. doi: 10.3389/fimmu.2022.1055235. eCollection 2022.
5
Cetuximab and paclitaxel combination therapy for recurrent basaloid squamous cell carcinoma in the ethmoid sinus.西妥昔单抗联合紫杉醇治疗筛窦复发性基底样鳞状细胞癌。
Auris Nasus Larynx. 2021 Dec;48(6):1189-1192. doi: 10.1016/j.anl.2020.07.002. Epub 2020 Jul 16.
6
Intracranial complete response to toripalimab and anlotinib in a patient with recurrent brain metastases of small cell lung cancer after failure of second-line maintenance therapy: a case report.小细胞肺癌二线维持治疗失败后复发性脑转移患者对托瑞帕利单抗和安罗替尼的颅内完全缓解：一例报告
Transl Cancer Res. 2022 Sep;11(9):3337-3342. doi: 10.21037/tcr-22-666.
7
Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma.人乳头瘤病毒感染与阴茎癌围手术期淋巴结放疗结局的关系。
Eur Urol Oncol. 2021 Oct;4(5):802-810. doi: 10.1016/j.euo.2020.10.011. Epub 2020 Nov 14.
8
Anlotinib Combined With Chemotherapy for Recurrence of Pulmonary Sarcomatoid Cancer Previously Surgically Treated: A Case Report and Literature Review.安罗替尼联合化疗治疗既往手术治疗后复发的肺肉瘤样癌：病例报告及文献复习
Front Oncol. 2021 May 11;11:639168. doi: 10.3389/fonc.2021.639168. eCollection 2021.
9
Management of Advanced Penile Cancer.晚期阴茎癌的治疗管理。
Mayo Clin Proc. 2021 Mar;96(3):720-732. doi: 10.1016/j.mayocp.2020.06.031. Epub 2020 Dec 9.
10
Sintilimab-Induced Diabetic Ketoacidosis in a Patient with Radiation and Multichemorefractory Penile Cancer: A Case Report and Literature Review.信迪利单抗致放射性和多化疗难治性阴茎癌患者糖尿病酮症酸中毒：病例报告及文献复习。
Curr Oncol. 2022 Oct 25;29(11):7987-7993. doi: 10.3390/curroncol29110632.

引用本文的文献

1
Evidence-Based Recommendations on the Use of Immunotherapies and Monoclonal Antibodies in the Treatment of Male Reproductive Cancers.关于免疫疗法和单克隆抗体在男性生殖系统癌症治疗中应用的循证推荐意见。
Curr Oncol. 2025 Feb 14;32(2):108. doi: 10.3390/curroncol32020108.

本文引用的文献

1
Combined treatment with anlotinib and chemotherapy for advanced esophageal squamous cell carcinoma improved patient survival: a case report.安罗替尼联合化疗治疗晚期食管鳞状细胞癌可改善患者生存：病例报告
Am J Transl Res. 2020 Oct 15;12(10):6578-6583. eCollection 2020.
2
Sarcomatoid carcinoma of the gallbladder: a case report.胆囊肉瘤样癌：一例报告。
J Int Med Res. 2020 Jun;48(6):300060520935283. doi: 10.1177/0300060520935283.
3
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.安罗替尼：一种新型多靶点酪氨酸激酶抑制剂的临床开发。
J Hematol Oncol. 2018 Sep 19;11(1):120. doi: 10.1186/s13045-018-0664-7.
4
Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.一项多中心、随机、双盲、安慰剂对照的 III 期临床试验表明，安罗替尼可改善晚期非小细胞肺癌患者的生活质量。
Lung Cancer. 2018 Aug;122:32-37. doi: 10.1016/j.lungcan.2018.05.013. Epub 2018 May 18.
5
Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel.腹股沟淋巴结清扫术后辅助放疗在淋巴结阳性阴茎癌中的风险和获益：欧洲泌尿外科学会阴茎癌指南专家组的系统评价。
Eur Urol. 2018 Jul;74(1):76-83. doi: 10.1016/j.eururo.2018.04.003. Epub 2018 Apr 24.
6
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.高度强效且选择性的血管内皮生长因子受体-2抑制剂安罗替尼的临床前特征
Cancer Sci. 2018 Apr;109(4):1207-1219. doi: 10.1111/cas.13536. Epub 2018 Mar 25.
7
Is there a benefit to adjuvant radiation in stage III penile cancer after lymph node dissection? Findings from the National Cancer Database.阴茎癌Ⅲ期患者行淋巴结清扫术后辅助放疗是否有益？来自国家癌症数据库的研究结果。
Urol Oncol. 2018 Mar;36(3):92.e11-92.e16. doi: 10.1016/j.urolonc.2017.11.005. Epub 2017 Nov 27.
8
Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study.辅助盆腔放疗与盆腔淋巴结清扫术后盆腔淋巴结阳性阴茎癌患者的生存率提高及疾病复发减少相关：一项多机构研究。
Urol Oncol. 2017 Oct;35(10):605.e17-605.e23. doi: 10.1016/j.urolonc.2017.06.001. Epub 2017 Jun 27.
9
Contemporary management of patients with penile cancer and lymph node metastasis.阴茎癌伴淋巴结转移患者的当代治疗策略。
Nat Rev Urol. 2017 Jun;14(6):335-347. doi: 10.1038/nrurol.2017.47. Epub 2017 Apr 11.
10
Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab.头颈部晚期鳞状细胞癌：西妥昔单抗的当前作用
ORL J Otorhinolaryngol Relat Spec. 2016;78(6):320-333. doi: 10.1159/000455891. Epub 2017 Jan 27.